TSX:INCR-U - Toronto Stock Exchange - IL0011063760 - Common Stock - Currency: USD
TSX:INCR-U (8/14/2023, 7:00:00 PM)
1.53
+0.06 (+4.08%)
The current stock price of INCR-U.CA is 1.53 USD. In the past month the price decreased by -35.17%. In the past year, price decreased by -79.6%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
BHC.CA | BAUSCH HEALTH COS INC | 1.51 | 2.92B | ||
CRON.CA | CRONOS GROUP INC | 14.94 | 1.04B | ||
TLRY.CA | TILRAY BRANDS INC | N/A | 880.42M | ||
DHT-UN.CA | DRI HEALTHCARE TRUST | 6.63 | 783.66M | ||
GUD.CA | KNIGHT THERAPEUTICS INC | 56.09 | 614.84M | ||
DHT-U.CA | DRI HEALTHCARE TRUST | 4.81 | 568.88M | ||
ACB.CA | AURORA CANNABIS INC | 123.4 | 347.06M | ||
WEED.CA | CANOPY GROWTH CORP | N/A | 337.86M | ||
CPH.CA | CIPHER PHARMACEUTICALS INC | 24.34 | 311.80M | ||
NGEN.CA | NERVGEN PHARMA CORP | N/A | 247.83M | ||
OGI.CA | ORGANIGRAM GLOBAL INC | 30.83 | 247.68M | ||
HITI.CA | HIGH TIDE INC | N/A | 243.60M |
InterCure Ltd. engages in the business of medical cannabis and biomedicine. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
Intercure Ltd
Medinat HaYehudim 85
Herzliya 4676670 IL
CEO: Alexander Rabinovich
Employees: 350
Phone: 972774605012.0
The current stock price of INCR-U.CA is 1.53 USD. The price increased by 4.08% in the last trading session.
The exchange symbol of Intercure Ltd is INCR-U and it is listed on the Toronto Stock Exchange exchange.
INCR-U.CA stock is listed on the Toronto Stock Exchange exchange.
8 analysts have analysed INCR-U.CA and the average price target is 0.03 USD. This implies a price decrease of -98.25% is expected in the next year compared to the current price of 1.53. Check the Intercure Ltd stock analysts ratings, price target forecast and up-and down grades for more detailed information.
Intercure Ltd (INCR-U.CA) has a market capitalization of 69.73M USD. This makes INCR-U.CA a Micro Cap stock.
Intercure Ltd (INCR-U.CA) currently has 350 employees.
Intercure Ltd (INCR-U.CA) has a resistance level at 1.58. Check the full technical report for a detailed analysis of INCR-U.CA support and resistance levels.
The Revenue of Intercure Ltd (INCR-U.CA) is expected to grow by 20.95% in the next year. Check the estimates tab for more information on the INCR-U.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
INCR-U.CA does not pay a dividend.
The PE ratio for Intercure Ltd (INCR-U.CA) is 6.12. This is based on the reported non-GAAP earnings per share of 0.25 and the current share price of 1.53 USD. Check the full fundamental report for a full analysis of the valuation metrics for INCR-U.CA.
ChartMill assigns a fundamental rating of 5 / 10 to INCR-U.CA. While INCR-U.CA is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months INCR-U.CA reported a non-GAAP Earnings per Share(EPS) of 0.25. The EPS increased by 86.38% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 7.77% | ||
ROA | 3.62% | ||
ROE | 6.29% | ||
Debt/Equity | 0.24 |
ChartMill assigns a Buy % Consensus number of 85% to INCR-U.CA. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -141.25% and a revenue growth 20.95% for INCR-U.CA